286 related articles for article (PubMed ID: 32748758)
1. Therapy Resistance in Cancers: Phenotypic, Metabolic, Epigenetic and Tumour Microenvironmental Perspectives.
Zahan T; Das PK; Akter SF; Habib R; Rahman MH; Karim MR; Islam F
Anticancer Agents Med Chem; 2020; 20(18):2190-2206. PubMed ID: 32748758
[TBL] [Abstract][Full Text] [Related]
2. Cancer Stem Cells and Targeting Strategies.
Barbato L; Bocchetti M; Di Biase A; Regad T
Cells; 2019 Aug; 8(8):. PubMed ID: 31426611
[TBL] [Abstract][Full Text] [Related]
3. Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer.
Du B; Shim JS
Molecules; 2016 Jul; 21(7):. PubMed ID: 27455225
[TBL] [Abstract][Full Text] [Related]
4. Stem cell programs in cancer initiation, progression, and therapy resistance.
Huang T; Song X; Xu D; Tiek D; Goenka A; Wu B; Sastry N; Hu B; Cheng SY
Theranostics; 2020; 10(19):8721-8743. PubMed ID: 32754274
[TBL] [Abstract][Full Text] [Related]
5. Tumour microenvironment on mitochondrial dynamics and chemoresistance in cancer.
Han Y; Cho U; Kim S; Park IS; Cho JH; Dhanasekaran DN; Song YS
Free Radic Res; 2018 Dec; 52(11-12):1271-1287. PubMed ID: 29607684
[TBL] [Abstract][Full Text] [Related]
6. Targeting EMT in Cancer with Repurposed Metabolic Inhibitors.
Ramesh V; Brabletz T; Ceppi P
Trends Cancer; 2020 Nov; 6(11):942-950. PubMed ID: 32680650
[TBL] [Abstract][Full Text] [Related]
7. Cancer stem cell (CSC) resistance drivers.
Najafi M; Mortezaee K; Majidpoor J
Life Sci; 2019 Oct; 234():116781. PubMed ID: 31430455
[TBL] [Abstract][Full Text] [Related]
8. Stochastic modeling of phenotypic switching and chemoresistance in cancer cell populations.
Kumar N; Cramer GM; Dahaj SAZ; Sundaram B; Celli JP; Kulkarni RV
Sci Rep; 2019 Jul; 9(1):10845. PubMed ID: 31350465
[TBL] [Abstract][Full Text] [Related]
9. Epithelial mesenchymal transition in colorectal cancer: Seminal role in promoting disease progression and resistance to neoadjuvant therapy.
Bhangu A; Wood G; Mirnezami A; Darzi A; Tekkis P; Goldin R
Surg Oncol; 2012 Dec; 21(4):316-23. PubMed ID: 22981546
[TBL] [Abstract][Full Text] [Related]
10. Insights into new mechanisms and models of cancer stem cell multidrug resistance.
Garcia-Mayea Y; Mir C; Masson F; Paciucci R; LLeonart ME
Semin Cancer Biol; 2020 Feb; 60():166-180. PubMed ID: 31369817
[TBL] [Abstract][Full Text] [Related]
11. Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance.
Fiori ME; Di Franco S; Villanova L; Bianca P; Stassi G; De Maria R
Mol Cancer; 2019 Mar; 18(1):70. PubMed ID: 30927908
[TBL] [Abstract][Full Text] [Related]
12. Identification of the specific epigenetic alterations associated with chemo-resistance via reprogramming of cancer cells.
Kim JJ; Rai R
Med Hypotheses; 2015 Dec; 85(6):710-4. PubMed ID: 26527497
[TBL] [Abstract][Full Text] [Related]
13. Tumour Cell Secretome in Chemoresistance and Tumour Recurrence.
Madden EC; Gorman AM; Logue SE; Samali A
Trends Cancer; 2020 Jun; 6(6):489-505. PubMed ID: 32460003
[TBL] [Abstract][Full Text] [Related]
14. The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma.
Xia S; Pan Y; Liang Y; Xu J; Cai X
EBioMedicine; 2020 Jan; 51():102610. PubMed ID: 31918403
[TBL] [Abstract][Full Text] [Related]
15. Addressing intra-tumoral heterogeneity and therapy resistance.
Rybinski B; Yun K
Oncotarget; 2016 Nov; 7(44):72322-72342. PubMed ID: 27608848
[TBL] [Abstract][Full Text] [Related]
16. Epithelial-mesenchymal-transition-inducing transcription factors: new targets for tackling chemoresistance in cancer?
van Staalduinen J; Baker D; Ten Dijke P; van Dam H
Oncogene; 2018 Nov; 37(48):6195-6211. PubMed ID: 30002444
[TBL] [Abstract][Full Text] [Related]
17. Epithelial-mesenchymal transition and drug resistance: role, molecular mechanisms, and therapeutic strategies.
Sui H; Zhu L; Deng W; Li Q
Oncol Res Treat; 2014; 37(10):584-9. PubMed ID: 25342509
[TBL] [Abstract][Full Text] [Related]
18. Alternative splicing modulates cancer aggressiveness: role in EMT/metastasis and chemoresistance.
Roy Burman D; Das S; Das C; Bhattacharya R
Mol Biol Rep; 2021 Jan; 48(1):897-914. PubMed ID: 33400075
[TBL] [Abstract][Full Text] [Related]
19. Epithelial-mesenchymal transition in human cancer: comprehensive reprogramming of metabolism, epigenetics, and differentiation.
Li L; Li W
Pharmacol Ther; 2015 Jun; 150():33-46. PubMed ID: 25595324
[TBL] [Abstract][Full Text] [Related]
20. The relationship between platinum drug resistance and epithelial-mesenchymal transition.
Brozovic A
Arch Toxicol; 2017 Feb; 91(2):605-619. PubMed ID: 28032148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
